Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 40.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 50,472 shares of the biotechnology company’s stock after selling 34,962 shares during the period. Allspring Global Investments Holdings LLC owned about 0.05% of Sarepta Therapeutics worth $3,125,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Sarepta Therapeutics by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock worth $1,104,701,000 after purchasing an additional 117,904 shares during the last quarter. Capital International Investors grew its stake in shares of Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after buying an additional 2,437,855 shares during the period. Farallon Capital Management LLC boosted its position in shares of Sarepta Therapeutics by 11.1% during the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock worth $348,368,000 after purchasing an additional 285,100 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in shares of Sarepta Therapeutics by 0.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company’s stock worth $237,901,000 after purchasing an additional 10,343 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Sarepta Therapeutics by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company’s stock worth $207,538,000 after purchasing an additional 9,999 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on SRPT shares. Cantor Fitzgerald reiterated a “neutral” rating on shares of Sarepta Therapeutics in a report on Monday, June 16th. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research report on Wednesday, June 25th. UBS Group dropped their target price on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. Robert W. Baird lowered their price objective on shares of Sarepta Therapeutics from $60.00 to $30.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 17th. Finally, BMO Capital Markets downgraded shares of Sarepta Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $120.00 to $70.00 in a report on Monday, June 16th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $60.88.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $18.22 on Monday. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. The stock has a market cap of $1.79 billion, a P/E ratio of -6.77 and a beta of 0.45. The company has a 50-day moving average of $35.34 and a two-hundred day moving average of $74.80. Sarepta Therapeutics, Inc. has a 12-month low of $16.88 and a 12-month high of $154.90.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The business’s quarterly revenue was up 80.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.73 EPS. As a group, research analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.